Department of Urology (JH, DvM, JWB, IMT) and Departments of Medicine-Clinical Immunology (GF), Medicine-Medicine Oncology (GW) and Pathology (DAT), University of Texas Health Science Center at San Antonio, Institute for Drug Development, Cancer Therapy Research Center (SS) and South Texas Veterans Healthcare System, Audie L. Murphy Division (GW, DAT, JWB), San Antonio, Texas
Auto-generated profile, based on publicly available information
Geoffrey Weiss
Department of Urology (JH, DvM, JWB, IMT) and Departments of Medicine-Clinical Immunology (GF), Medicine-Medicine Oncology (GW) and Pathology (DAT), University of Texas Health Science Center at San Antonio, Institute for Drug Development, Cancer Therapy Research Center (SS) and South Texas Veterans Healthcare System, Audie L. Murphy Division (GW, DAT, JWB), San Antonio, Texas
Studies suggest that vitamin E may decrease the risk of prostate cancer. The Prevention Research Veteran Affairs E-vitamin Nutrition Trial is a randomized, double-blind, placebo controlled study designed to assess the effects of vitamin E supplementation on biomarkers associated with prostate cancer risk in peripheral blood and prostate tissue. A total of 44 patients with increased prostate specific antigen (PSA) and/or abnormal digital rectal examination on initial evaluation were randomized to receive 400 IU vitamin E (22) vs placebo (22). Serum vitamin E, PSA, dehydroepiandrosterone, testosterone and insulin-like growth factor-1 (IGF-1) were measured in the 2 groups at baseline and then at 3-month intervals. Results are reported in 28 patients (placebo in 14 and vitamin E in 14) who completed the treatment as specified by the protocol. Serum Vitamin E was significantly higher in patients on vitamin E supplementation. α-Tocopherol supplementation did not affect the levels of PSA, serum androgens (testosterone and dehydroepiandrosterone) or (IGF-1). Serum α-tocopherol is increased by oral supplementation of vitamin E. We found that α-tocopherol supplementation has no effect on serum androgens, IGF-1 or PSA. The lack of an effect of vitamin supplementation on PSA avoids any bias in the diagnosis of prostate cancer in vitamin E treated patients. Our results suggest that a decrease in prostate cancer risk with α-tocopherol is likely to occur through a mechanism that is nonhormonal and independent of IGF-1.